Memecylon edule

Memecylon edule leaf and flower extracts contain ursolic acid, stearic acid, 1,2,3-benzenetriol (pyrogallol), and diverse flavonoids and tannins, with ursolic acid demonstrating topoisomerase II inhibition via molecular docking and dose-dependent antiproliferative cytotoxicity against U-937 and HL-60 cancer cell lines. In vitro antimicrobial assays recorded a minimum inhibitory concentration of 62.5 µg/mL against pathogens including Streptococcus pneumoniae and Salmonella typhimurium, and flower ethyl acetate extracts achieved up to 94.48% antibiofilm inhibition against Pseudomonas aeruginosa.

Origin & History

Memecylon edule Roxb. is a tropical shrub or small tree native to South and Southeast Asia, distributed across India (notably the Shervarayan and Kolli Hills of Tamil Nadu), Sri Lanka, Malaysia, and parts of the Indo-Malayan archipelago. It thrives in humid tropical forests, rocky hillsides, and coastal scrublands at low to moderate elevations, typically in well-drained lateritic or sandy soils under partial shade. The plant is not commercially cultivated at scale; aerial parts including leaves and flowers are primarily wildcrafted by indigenous communities for traditional medicinal use.

Historical & Cultural Context

Memecylon edule has a documented history of use in the traditional medicine systems of southern India, particularly among tribal communities of the Shervarayan Hills and Kolli Hills of Tamil Nadu, where it is employed for conditions including leucorrhoea (anti-leucorrhoeic use), spasms, fever, and inflammatory disorders. In Malaysian ethnomedicine, the plant is associated with the treatment of diabetes, aligning with its pharmacologically plausible hypoglycaemic activity and justifying its categorization as a Southeast Asian antidiabetic herb. Preparations traditionally involve the collection of fresh aerial parts—leaves and flowers—followed by aqueous decoction or maceration, with some communities using bark preparations for dermatological conditions. The plant's role in green nanotechnology has also emerged recently, with leaf extracts employed as reducing agents in the biosynthesis of nanoparticles, representing a contemporary extension of its phytochemical utility beyond classical ethnomedicine.

Health Benefits

- **Antidiabetic and Hypoglycaemic Activity**: Ethnomedicinal use across Malaysia and southern India documents hypoglycaemic application; aqueous and ethyl acetate leaf extracts are considered candidate nutraceuticals for blood glucose management, though in vivo and clinical validation remain limited.
- **Antiproliferative and Anticancer Potential**: Ursolic acid isolated from ethyl acetate leaf extracts inhibited topoisomerase II via molecular docking and reduced viability of U-937 lymphoma cells to 73.15 ± 2.01% and HL-60 leukemia cells to 69.64 ± 0.68% at 3.13 µmol/mL, indicating dose-dependent cytotoxicity.
- **Antimicrobial Action**: Leaf extracts demonstrated MIC of 62.5 µg/mL and MBC of 1 mg/mL against S. pneumoniae and Salmonella typhimurium (inhibition zone 25 mm), attributed to stearic acid and phenolic compounds disrupting microbial membrane integrity.
- **Antibiofilm Activity**: Flower ethyl acetate extracts achieved up to 94.48% inhibition of biofilm formation against P. aeruginosa and 37.40% against E. coli by suppressing microbial cell adhesion, suggesting therapeutic potential against drug-resistant biofilm-associated infections.
- **Antioxidant Activity**: Phenolic constituents including 1,2,3-benzenetriol (pyrogallol), epigallocatechin gallate, and myricetin confer free radical scavenging capacity; aqueous extracts have been characterized as candidate nutraceutical antioxidants in preliminary phytochemical assessments.
- **Anti-inflammatory and Hepatoprotective Properties**: Traditional ethnomedicinal use in India attributes anti-inflammatory, spasmolytic, and hepatoprotective effects to the plant; triterpenoids including ursolic acid are consistent with known anti-inflammatory mechanisms such as NF-κB pathway modulation, though direct experimental confirmation in M. edule is lacking.
- **Larvicidal and Antiviral Applications**: Ethnobotanical records document larvicidal and antiviral uses; these activities are attributed to the cumulative effect of tannins, saponins, and triterpenoid fractions, with no quantified in vitro or in vivo data currently published.

How It Works

Ursolic acid (3β-hydroxyurs-12-en-28-oic acid), a pentacyclic triterpenoid isolated from ethyl acetate leaf fractions, inhibits DNA topoisomerase II as demonstrated by molecular docking studies, thereby impairing DNA replication and inducing apoptosis in cancer cell lines such as U-937 and HL-60. Stearic acid and phenolic compounds including 1,2,3-benzenetriol (pyrogallol) disrupt bacterial cell membrane lipid bilayers, compromising membrane integrity and leading to cytoplasmic leakage, which accounts for the observed antimicrobial activity at MIC 62.5 µg/mL. Flavonoids such as epigallocatechin gallate and myricetin scavenge reactive oxygen species through hydrogen atom transfer and single-electron transfer mechanisms, contributing to the antioxidant profile, while tannins inhibit bacterial cell adhesion to surfaces, explaining the robust antibiofilm activity in flower extracts. The hypoglycaemic effects reported ethnopharmacologically likely involve inhibition of α-glucosidase or enhancement of insulin sensitivity consistent with the activity of ursolic acid and flavonoids seen in related species, but specific receptor-level or enzyme-level data for M. edule itself have not been published.

Scientific Research

The available body of evidence for Memecylon edule consists exclusively of in vitro laboratory studies and molecular docking computational analyses; no randomized controlled trials, animal pharmacology studies, or human clinical investigations have been published as of the current literature review. Phytochemical characterization via GC-MS of ethyl acetate leaf extracts identified stearic acid at 20.19% and 1,2,3-benzenetriol at 11.30% peak area, while ursolic acid was isolated and confirmed structurally from the same fraction with antiproliferative assays conducted on two leukemia/lymphoma cell lines (U-937 and HL-60) at a single concentration point of 3.13 µmol/mL. Antimicrobial and antibiofilm studies employed standard disk diffusion and MIC/MBC broth microdilution methods against a limited panel of bacterial strains, yielding reproducible but non-clinically validated results. The overall evidence base is preclinical and exploratory, and the transition from in vitro bioactivity data to demonstrated in vivo or clinical efficacy has not been made for any indication.

Clinical Summary

No human clinical trials investigating Memecylon edule or its isolated constituents for any health outcome have been conducted or reported in the peer-reviewed literature. The most advanced experimental data derive from in vitro antiproliferative studies showing 73.15 ± 2.01% cell viability reduction in U-937 cells and 69.64 ± 0.68% in HL-60 cells at a fixed concentration of 3.13 µmol/mL ursolic acid, representing dose-response characterization without IC50 determination or in vivo confirmation. Antimicrobial outcomes such as MIC of 62.5 µg/mL and antibiofilm inhibition up to 94.48% are from microplate and agar-based in vitro assays and cannot be extrapolated to clinical dosing without pharmacokinetic data. Confidence in clinical applicability remains very low; M. edule should be regarded as a candidate plant for further preclinical and eventual clinical investigation rather than an evidence-based therapeutic agent.

Nutritional Profile

Memecylon edule leaves and flowers contain a diverse array of secondary metabolites rather than notable primary nutritional macronutrients; no food-use proximate composition data (protein, carbohydrate, fat content) are available. Identified phytochemicals by GC-MS in ethyl acetate leaf extracts include stearic acid (a C18 saturated fatty acid, 20.19% peak area), tetracosanoic acid trimethylsilyl ester (lignoceric acid derivative, 8.39%), and 1,2,3-benzenetriol/pyrogallol (11.30%), alongside 2,2-dimethylglutaric acid (8.39%) and 4-vinylphenol (1.73%). Polyphenolic constituents include epigallocatechin gallate (EGCG), myricetin, and other flavonoids; triterpenoids including ursolic acid; tannins; saponins; carotenoids; glucose; and amino acids have been qualitatively identified. Bioavailability of these compounds from crude plant preparations is unknown, as no pharmacokinetic studies specific to M. edule extracts have been conducted.

Preparation & Dosage

- **Ethyl Acetate Leaf Extract (Research Grade)**: Used at 62.5 µg/mL for antimicrobial testing and 3.13 µmol/mL ursolic acid equivalent for antiproliferative assays; no human-equivalent dose established.
- **Aqueous Leaf Infusion (Traditional)**: Prepared by decocting fresh or dried leaves in water; used in Indian folk medicine for hypoglycaemic and anti-inflammatory purposes without standardized dose or concentration data.
- **Flower Ethyl Acetate Extract (Research Grade)**: Evaluated for antibiofilm activity at unspecified concentrations yielding 94.48% P. aeruginosa biofilm inhibition; not formulated for human use.
- **Ursolic Acid Isolate**: Extracted via activity-guided fractionation of ethyl acetate leaf extract; tested in vitro at 3.13 µmol/mL; no commercial supplement standardization for M. edule-sourced ursolic acid exists.
- **No Standardized Commercial Form**: Capsule, tablet, tincture, or standardized extract formulations have not been developed or approved; all dosage information is experimental and not applicable to human supplementation.

Synergy & Pairings

No experimentally validated synergistic combinations involving Memecylon edule extracts or its isolated constituents have been reported in the literature. Theoretically, ursolic acid from M. edule may exhibit additive or synergistic antiproliferative effects when combined with other topoisomerase II inhibitors or flavonoid-rich extracts such as green tea (EGCG), given overlapping mechanisms; however, this has not been tested. The combination of M. edule's phenolic fraction with zinc or silver nanoparticle synthesis (as in green nanotechnology applications) has been explored, but this does not represent a nutritional or pharmacological synergy relevant to human supplementation.

Safety & Interactions

No formal safety studies, toxicological assessments, or adverse event reports for Memecylon edule or its isolated constituents have been published; the safety profile is therefore entirely uncharacterized in human subjects. In vitro studies at concentrations of 62.5 µg/mL to 3.13 µmol/mL did not report cytotoxicity to normal cell lines, but the absence of cytotoxicity data in non-cancerous primary cells and the complete lack of in vivo toxicological data preclude any safety conclusions. No drug interactions have been documented; however, theoretical interactions with antidiabetic medications (additive hypoglycaemic risk), anticoagulants (given tannin and fatty acid content), and cytotoxic chemotherapy agents (ursolic acid's topoisomerase II activity) cannot be excluded. Use during pregnancy or lactation is not recommended given the absence of safety data; individuals with known plant allergies within the Melastomataceae family should exercise caution.